Gilead Sciences wins Trodelvy approvals, shares supported by oncology focus
29.06.2026 - 09:07:15 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 09:06.
Gilead Sciences (US3755581036) expands its oncology footprint with fresh regulatory approvals for Trodelvy in first-line metastatic triple-negative breast cancer, as documented by recent U.S. FDA and European Commission decisions reported by MarketScreener and Dow Jones. The Nasdaq-listed biotech also underpins this focus with a planned acquisition of German cancer drug developer Tubulis for up to 5 billion dollars, according to TradingKey.
Trodelvy advances in breast cancer
On June 24, 2026, the U.S. Food and Drug Administration approved Trodelvy as a first-line treatment for adults with metastatic triple-negative breast cancer (mTNBC), extending the drug’s label beyond later-line use, according to a MarketScreener summary of Gilead and Dow Jones reports. The approval targets patients whose tumors do not express hormone receptors or HER2 and who often have limited treatment options.
A day earlier, the European Commission granted marketing authorization for Trodelvy in the same first-line metastatic triple-negative breast cancer setting, as relayed in the same MarketScreener compilation. These coordinated decisions in the United States and European Union position Trodelvy as a front-line standard-of-care candidate across two major regulatory regions.
Oncology pipeline and analyst view
Gilead is also set to acquire German oncology specialist Tubulis for up to 5 billion dollars, aiming to strengthen its antibody-drug conjugate platform and cancer portfolio, according to a detailed note on TradingKey that cites company confirmations. The deal is expected to enhance Gilead’s presence in solid tumor indications and broaden its access to the U.S. cancer therapeutics market.
Analyst aggregators such as MarketScreener indicate an average price target around 157.57 dollars for Gilead shares, with multiple brokers covering the Nasdaq-listed stock as a large-cap U.S. biopharma name. The company’s market capitalization stood near 158.8 billion dollars at a recent close, highlighting its scale within the global healthcare sector, as shown by TradingKey data.
All news and analysis on the Gilead Sciences shares
Further corporate news, price data and regulatory updates on Gilead Sciences are compiled in the dedicated topic section on ad-hoc-news.de.
The product behind the stock
Trodelvy is an antibody-drug conjugate designed to deliver a cytotoxic payload directly to cancer cells expressing the Trop-2 antigen, aiming to limit off-target effects while improving efficacy in solid tumors such as metastatic triple-negative breast cancer. Beyond Trodelvy, Gilead’s portfolio spans antiviral therapies for HIV and hepatitis, alongside expanding oncology assets that leverage targeted and immune-based mechanisms.
Where the stock trades today
The Gilead Sciences shares (US3755581036) last closed on June 26, 2026 on the Nasdaq at 127.88 dollars, giving the company a market capitalization of about 158.8 billion dollars, according to TradingKey data.
Key data on the Gilead Sciences shares
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- WKN: 885823
- Ticker: GILD
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 16:00): 127.88 USD
- Market cap: 158.83 billion USD (as of 2026-06-26)
- Sector / industry: Health Care / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their individual financial situation.
